AB Science announced that an abstract on the long-term survival of
masitinib in ALS has been selected for a platform presentation at
the Annual Meeting of the Spanish Society of Neurology
PRESS RELEASE
RESULTS FROM LONG-TERM SURVIVAL ANALYSIS
OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS SELECTED FOR PLENARY
SPEECH AS “STAR
ORAL COMMUNICATION” AT THE
SPANISH SOCIETY OF NEUROLOGY ANNUAL MEETING
Paris, 20 September 2021, 7pm CET
AB Science SA (Euronext -
FR0010557264 - AB) today announced that an abstract on the
long-term survival of masitinib in amyotrophic lateral sclerosis
(ALS) has been selected for a platform presentation at the Annual
Meeting of the Spanish Society of Neurology, which will be held in
virtual format between November 22 and December 2, 2021.
This abstract has received the honor of being
designated as an extended ‘comunicación oral estelar’ (stellar oral
communication). During this event, which will be held in Spanish,
latest advances in the neurological field will be presented with
more than 3,000 national and international experts expected to
connect.
The presentation, titled ‘Long-term survival
analysis of masitinib in amyotrophic lateral sclerosis’, will be
delivered by Professor Josep Gamez M.D., Ph.D. (Director of the
Peripheral Nervous System Laboratory and Head of the Neuromuscular
Disorders Clinic at the Vall d'Hebron Research Institute,
Barcelona, Spain), a senior investigator from the masitinib phase
2/3 study (AB10015) in ALS [1].
Professor Gamez said, “Selection of this
abstract for a ‘comunicación oral estelar’ at the Spanish Society
of Neurology LXXIII Annual Meeting is an indication of the level of
interest being generated by long-term survival data from masitinib
study AB10015. We first suspected that masitinib may generate
improved survival in certain subgroups through observation of
patients enrolled in study AB10015 at the Vall d'Hebron Hospital's
ALS Unit [2]. Findings from the overall study long-term survival
analysis have confirmed this impression using a larger, multicenter
patient cohort, which also revealed that there is a greater
treatment effect when masitinib is initiated at an earlier stage of
disease [3]”.
References
[1] Mora JS, Genge A, Chio A, et al. Masitinib
as an add-on therapy to riluzole in patients with amyotrophic
lateral sclerosis: a randomized clinical trial. Amyotroph Lateral
Scler Frontotemporal Degener. 2020;21(1-2):5-14.
doi:10.1080/21678421.2019.1632346
[2] Gamez J. Vall d’Hebron participates in an
international study to validate masitinib for amyotrophic lateral
sclerosis treatment. VHIR. org News, 20 March, 2020.
http://en.vhir.org/portal1/news-detail.asp?t=vall-dhebron-participatesin-an-international-study-to-validatemasitinib-for-amyotrophic-lateral-sclerosistreatment&contentid=214927&s=actualitat
[3] Mora JS; Bradley WG; Chaverri D, et al.
Long-term Survival Analysis of Masitinib in Amyotrophic Lateral
Sclerosis. Ther Adv Neurol Disord 2021, Vol. 14: 1–16 doi:10.1177/
17562864211030365
About amyotrophic lateral
sclerosisAmyotrophic lateral sclerosis (ALS) is a fatal
motor neuron disorder that is characterized by progressive loss of
the upper and lower motor neurons at the spinal or bulbar level.
The disease belongs to a group of disorders known as motor neuron
diseases, which are characterized by the gradual degeneration and
death of motor neurons. In ALS, both the upper motor neurons and
the lower motor neurons degenerate or die, and stop sending
messages to muscles. The prevalence of ALS in western countries is
fairly uniform at 6 per 100,000 persons, corresponding to around
30,000 cases in Europe and 20,000 in the USA.The first drug
treatment for ALS, riluzole (Rilutek), was approved in 1995. In
Europe, there has been no new treatment approved since
riluzole.
About masitinibMasitinib is an
orally administered tyrosine kinase inhibitor that targets mast
cells and macrophages, important cells for immunity, through
inhibiting a limited number of kinases. Based on its unique
mechanism of action, masitinib can be developed in a large number
of conditions in oncology, in inflammatory diseases, and in certain
diseases of the central nervous system. In oncology due to its
immunotherapy effect, masitinib can have an effect on survival,
alone or in combination with chemotherapy. Through its activity on
mast cells and microglia and consequently the inhibition of the
activation of the inflammatory process, masitinib can have an
effect on the symptoms associated with some inflammatory and
central nervous system diseases and the degeneration of these
diseases.
About AB ScienceFounded in
2001, AB Science is a pharmaceutical company specializing in the
research, development and commercialization of protein kinase
inhibitors (PKIs), a class of targeted proteins whose action are
key in signaling pathways within cells. Our programs target only
diseases with high unmet medical needs, often lethal with short
term survival or rare or refractory to previous line of treatment.
AB Science has developed a proprietary portfolio of molecules and
the Company’s lead compound, masitinib, has already been registered
for veterinary medicine and is developed in human medicine in
oncology, neurological diseases, inflammatory diseases and viral
diseases. The company is headquartered in Paris, France, and listed
on Euronext Paris (ticker: AB).
Further information is available on AB Science’s website:
www.ab-science.com.
Forward-looking Statements - AB
ScienceThis press release contains forward-looking
statements. These statements are not historical facts. These
statements include projections and estimates as well as the
assumptions on which they are based, statements based on projects,
objectives, intentions and expectations regarding financial
results, events, operations, future services, product development
and their potential or future performance.
These forward-looking statements can often be
identified by the words "expect", "anticipate", "believe",
"intend", "estimate" or "plan" as well as other similar terms.
While AB Science believes these forward-looking statements are
reasonable, investors are cautioned that these forward-looking
statements are subject to numerous risks and uncertainties that are
difficult to predict and generally beyond the control of AB Science
and which may imply that results and actual events significantly
differ from those expressed, induced or anticipated in the
forward-looking information and statements. These risks and
uncertainties include the uncertainties related to product
development of the Company which may not be successful or to the
marketing authorizations granted by competent authorities or, more
generally, any factors that may affect marketing capacity of the
products developed by AB Science, as well as those developed or
identified in the public documents published by AB Science. AB
Science disclaims any obligation or undertaking to update the
forward-looking information and statements, subject to the
applicable regulations, in particular articles 223-1 et seq. of the
AMF General Regulations.
For additional information, please contact:
AB ScienceFinancial
Communication & Media Relations investors@ab-science.com
Media Relations – USA
RooneyPartnersKate
Barrettekbarrette@rooneyco.com
+1 646 432 0191
Media Relations – France
NewCapArthur
Rouilléarouille@newcap.fr
+33 (0)1 44 71 00 15
Ab Science (EU:AB)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Ab Science (EU:AB)
Historical Stock Chart
Von Apr 2023 bis Apr 2024